Regulatory

Source: Immuno-Oncology News, March 2019 The U.S. Food and Drug Administration has approved the use of Keytruda(pembrolizumab) as a treatment for melanoma patients with stage 3 disease — cancer cells have…

Source: Pharma Field, February 2019 NICE recommends new treatment for adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Pierre Fabre welcomes the National Institute for Health…

Source: Pharmaceutical Technology, February 2019 Chinese Sino Pharmaceutical has announced that China’s National Medical Products Administration has approved its subsidiary Chia-Tai Tianqing Pharmaceutical’s anti-tumour drug lenalidomide for multiple melanoma. The…

Source: Fierce Pharma, February 2019 Thanks to new guidance from England’s drug cost watchdog, Novartis and Roche will be getting some fresh targeted melanoma competition from French pharma lab Pierre…